Session 12: Treatment Strategies in Chronic Leukemias and Introduction to CAR-T Therapies

3:30pm – 4:30pm

Program Overview

Chronic lymphocytic (CLL) and chronic myelogenous (CML) leukemia are commonly diagnosed and treated by community oncologists. Whereas in the past, these hematologic malignancies were considered incurable, new therapies have challenged that notion. Tyrosine kinase inhibitors (TKIs) annihilated the concept of CML as a poorly controlled disease, and most patients are now expected to live a normal life, with good quality of life. New testing procedures have now suggested that some patients may be “cured” such that ongoing chronic pharmaceutical intervention may be interrupted or discontinued. Identifying new targets in CLL has similarly changed the paradigm of intervention to the possibility of “cure” using a more aggressive and multiagent approach. A new form of immunotherapy, using CAR-T cells, initially used in acute leukemias, now appears to be applicable to CLL as well, with encouraging results. New molecular tests to identify subsets of patients who may benefit from targeted interventions, have also improved the chances of success in treating chronic leukemias. This session will review new concepts in diagnosis and treatment of CLL and CML.

Learning Objectives

  • Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
  • Evaluate the sequential and combination administration of chemotherapy and targeted agents to optimize survival in patients with chronic leukemia
  • Discuss current recommendations for diagnostic testing for chronic leukemia to facilitate treatment selection
  • Assess the safety and efficacy of approved and emerging therapies for primary and subsequent management of chronic leukemia with attention to cost/benefit and toxicity considerations
  • Evaluate communication strategies and resources to increase patient access and engagement

CME/CPE/CNE Information


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 hour (0.10 CEUs) of continuing education credit (UAN: 0418-9999-17-7206-L04-P).

This is an application-based activity.


1.0 ANCC Contact hours provided by Postgraduate Institute for Medicine

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

A statement of credit will be issued only upon receipt of a completed activity evaluation.

Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

FDA Disclosure

The contents of some CME/CPE/CNE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A certificate will be provided after submission of a completed evaluation form.

There is no fee associated with this program.

Special Services

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc).  Please contact MEDX Conference Planning prior to the live event at

Jointly provided by The Potomac Center for Medical Education, Postgraduate Institute of Medicine, and Rockpointe Oncology


This activity is supported by independent educational grants from AstraZeneca, Lilly, Novartis Pharmaceutical Corporation and Sanofi Genzyme.

For further information concerning Lilly grant funding visit

Faculty Information

Saar I Gill, MD, PhD
Assistant Professor of Medicine Hematology‐Oncology
University of Pennsylvania Perelman School of Medicine,
Philadelphia, PA